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Abstract
X-linked chronic granulomatous disease (XL-CGD), a rare primary immunodeficiency due to a defect in the gp91phox NADPH
oxidase subunit, results in recurrent, severe infection, inflammation, and autoimmunity. Patients have an absent, or significantly
reduced, neutrophil oxidative burst. Due to lyonization, XL-CGD carriers have a dual population of functional and non-
functional phagocytes and experience a range of symptoms including increased risk of autoimmunity, fatigue, and infection.
Patients with CGD have poorer quality of life (QoL) than normal controls. We evaluated QoL and psychological health in UK
XL-CGD carriers. Recruited participants completed theMedical Outcomes Study Short Form 36 version 2 (SF-36V2), providing
an overall score for mental and physical health. Psychological health was assessed using the Hospital Anxiety and Depression
Scale (HADS) questionnaire. Seventy-five XL-CGD carriers were recruited from 62 families, median age 43 years (range 3–77).
Fifty-six were mothers, 6 grandmothers, and 13 siblings. Sixty-two completed the SF36v2 and had reduced QoL scores com-
pared with adult CGD patients and a UK age-matched female control cohort, indicating a reduced QoL. Sixty-one completed a
HADS questionnaire. Over 40% experienced moderate or greater levels of anxiety with only one third being classified as normal.
Higher anxiety scores significantly correlated with higher depression scores, lower self-esteem, presence of joint or bowel
symptoms, and higher levels of fatigue (p < 0.05). This is the first study to evaluate QoL of XL-CGD carriers, and demonstrates
high rates of anxiety and significantly reduced QoL scores. XL-CGD carriers should be considered as potential patients and pro-
actively assessed and managed.
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Introduction
Chronic granulomatous disease (CGD) is a rare inborn error of
immunity in which a defect in one of the subunits of NADPH
oxidase results in a defective respiratory burst of phagocytic
cells, causing recurrent infection, inflammation, and autoim-
munity [1]. Patients with CGD who continue on maintenance
prophylactic treatment have poorer quality of life (QoL) than
healthy controls or CGD patients who underwent curative
hematopoietic stem cell transplantation [2].
CGD can be X-linked or autosomal recessive. Worldwide,
X-linked (XL) cases due to defects in the gp91phox subunit are
most common, and in the United Kingdom (UK), 70% of
cases are X-linked (XL) [3]. We, and others, have previously
described a range of symptoms in XL-CGD carriers. This
includes an increased risk of autoimmunity (in particular sys-
temic lupus erythematosus (SLE)–like symptoms), fatigue,
and, in some cases, infection, attributed to their dual
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population of functional and non-functional phagocytes [4–6].
Thus, there is a range of factors that may affect the QoL of
XL-CGD carriers. In addition to the symptoms above, they
also have risk factors around caring for a family member
with chronic disease and symptoms of anxiety and depres-
sion that may be associated with SLE. We aimed to evalu-
ate QoL and psychological health in XL-CGD carriers in
the UK.
Methods
XL-CGD carriers were identified through the UK CGD
Registry and approached either in person or through the mail.
Girls under the age of 16 years who did not know their carrier
status were not included in the study.
Carriers who were aware of their carrier status were
eligible and included where appropriate, irrespective of
their age. In families where the index case was deceased,
families were contacted if the physician caring for the fam-
ily deemed it appropriate or if there was continuing contact
with the family.
To assess health-related QoL, recruited participants
completed the Medical Outcomes Study Short Form 36
version 2 (SF-36 V2), which is a validated QoL question-
naire [7]. The SF36v2 provides a numerical score for 8
domains, along with an overall score for mental health
and physical health. Lower scores indicate poorer QoL. If
the index case had undergone HSCT, the SF-36 for the XL-
CGD carrier was delayed until a year had passed since the
procedure. HSCT is an intense period for family and pa-
tient alike, and the associated anxiety and distress, whilst
transient, may be evident for up to 6 months after the
transplant is completed [8, 9].
To assess psychological health, participants completed
questionnaires about self-esteem, and presence of anxiety
and depression symptoms, using the Hospital Anxiety and
Depression Scale (HADS) [10], a questionnaire compris-
ing 14 questions: 7 assessing anxiety and 7 assessing de-
pression. The score generated after completion of the ques-
tionnaire, for both anxiety and depression was categorized
and compared with population data [11] and scores from
patients with SLE [12, 13] and carers of patients with cys-
tic fibrosis [14].
Statistical analysis was carried out using STATA®
(StataCorp LLC, TX, USA). Data from the QoL question-
naires were inputted into the licenced software, which gen-
erated total scores for each domain. Each domain could
score a maximum of 100. Scores were compared by the
software with population data to produce norm-based
scores (NBS). Spearman’s correlation was used to assess
factors associated with anxiety and depression scores.
Results
Eighty families were identified from the UK CGD register,
and 75 XL-CGD carriers were recruited from 62 families.
The median age of participants was 43 (range 3–77) years.
Fifty-six were mothers, 6 grandmothers, and 13 siblings. In
8 families, the index case had died, but only 5 question-
naires were returned from these families, too few to facil-
itate a separate analysis.
Sixty-two participants completed the SF36v2, of which 55
(70%) were mothers of an index case. XL-CGD carriers had
similar, reduced QoL scores to adult CGD patients (Theresa
Cole, personal communication) and scored lower than CGD
patients in 4 domains (vitality, emotional, social function, and
mental health) (Fig. 1). Compared with a UK age-matched
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Fig. 1 Quality of life scores in X-
linked chronic granulomatous
disease carriers compared with
adult chronic granulomatous
disease patients (100 = normal)
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female control cohort, the scores for XL-CGD carriers were
significantly worse, indicating a reduced QoL (Table 1). There
was no significant difference in scores between carrier
mothers and other carrier relatives in any domain (Table 2).
There were significant associations between the SF36
Physical Component summary score and all physical symp-
toms except the skin manifestations of photosensitivity and
recurrent abscesses. There was a significant association with
degree of oxidative function, but no age-related association.
There were significant associations between the SF36 Mental
Component summary score and joint pains, gastrointestinal
and respiratory symptoms, number of fulfilled ARA criteria,
and recurrent skin abscesses. We found no correlation with
age of participant or degree of oxidative function. There was
no relationship between physical or mental quality of life and
transplant status of the index case.
Sixty-one participants returned a completed HADS ques-
tionnaire. The frequency of a pre-existing diagnosis of anxiety
or anxiety and depression is shown (Table 3). Only 1 XL-
CGD carrier suffered from isolated anxiety, but a greater num-
ber had a diagnosis of mixed anxiety and depression. Twelve
XL-CGD carriers had been prescribed antidepressants. Over
40% of XL-CGD carriers suffered from moderate or greater
levels of anxiety with only one third being classified as normal
(Table 4). The distribution of anxiety categories was similar,
irrespective of the relationship of the carrier to the index case.
Higher anxiety scores were significantly correlated with
higher depression scores, lower self-esteem, the presence of
joint or bowel symptoms, and higher levels of fatigue
(p < 0.05). There was no significant correlation of high anxi-
ety scores with age, relationship to the index case, or a diag-
nosis of SLE in the carrier (p > 0.05). There was no significant
difference in mean anxiety scores of the XL-CGD carriers
when considered with regard to age categories of the index
case or when compared with whether the index case had un-
dergone HSCT or remained on conventional therapy. There
was no significant difference in anxiety scores when com-
pared with published data from SLE patients [13].
With respect to the depression component, nearly three
quarters of the cohort were categorized as normal, with only
1 XL-CGD carrier in the severe category (Table 4). Depression
was considerably less prevalent than anxiety in the XL-CGD
carriers. Higher depression scores were significantly correlated
with higher anxiety scores, lower self-esteem, and higher fa-
tigue scores. There was no significant correlation of depression
scores with age, relationship to index case, and clinical symp-
toms (gastrointestinal and joint symptoms, diagnosis of SLE-
like disorder, and number of ARA SLE criteria met).
A comparison of HAD scores was made with published
data from carers of children with cystic fibrosis [14], a disease
which is inherited in an autosomal recessive manner (Table 5).
Table 1 Mean SF36v2 scores in XL-CGD carriers compared with UK
population data (100 = normal)
Domain CGD carriers UK norms
(female age 35–54) [15]
p value
Physical function 79.28 (29.4) 89.4 (18.3) < 0.001
Role physical 74.35 (32.2) 84.0 (32.0) 0.00235
Bodily pain 66.24 (30.5) 79.4 (22.0) 0.002
General health 56.31 (28.5) 74.1 (20.3) < 0.001
Vitality 44.98 (25.5) 58.2 (19.9) 0.002
Social function 69.68 (29.5) 86.7 (20.5) 0.001
Role emotional 71.88 (31.3) 80.3 (33.6) 0.0341
Mental health 63.16 (16.8) 71.6 (17.8) 0.005
Table 2 Correlation coefficient and p value for Mental Component and
Physical Component scores of quality of life with symptoms, degree of
neutrophil function, and age
MCS PCS
Joint symptoms − 0.33
0.0085
− 0.42
0.0009
IBD score (bowel symptoms) − 0.69
< 0.0001
− 0.50
< 0.0001
Respiratory score − 0.32
0.016
− 0.56
< 0.0001
Photosensitivity − 0.12
0.36
− 0.18
0.17
Recurrent abscesses − 0.34
0.0074
− 0.14
0.27
Ulcers −0.14
0.30
− 0.39
0.002
Number of ARA criteria − 0.31
0.016
− 0.39
0.002
% NOB 0.18
0.29
0.44
0.005
Age of participant − 0.55
0.67
− 0.23
0.07
Relationship to index case −0.049
0.71
− 0.046
0.73
Index case undergone HSCT − 0.13
0.45
0.17
0.32
MCS SF36 Mental Component summary score, PCS SF36 Physical
Component summary score, IBD inflammatory bowel disease, ARA
American Rheumatism Association, NOB neutrophil oxidative burst,
HSCT hematopoietic stem cell transplantation
Bold entries are significant p values
Table 3 Pre-existing anxiety and depression diagnoses and treatment
Diagnosis Number of XL-CGD carriers % affected
Anxiety 1 1.6
Depression 7 11.6
Mixed anxiety and depression 6 10
Prescribed antidepressants 12 20
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This demonstrated that anxiety scores were significantly
higher in XL-CGD carriers than the cystic fibrosis parents,
whilst the depression scores were higher but did not reach
significance.
Discussion
For patients affected by primary immunodeficiencies (PID),
research has primarily concentrated on elucidating the patho-
physiology of the disease, conducting epidemiological studies
to define the prevalence in different populations, and deter-
mining the prognosis with different treatment modalities that
are available. However, for patients, an important aspect of the
disease is the impact it has upon daily living. An association
between a reduced quality of life and chronic disease is well
recognized [16–18]. Previously, we have demonstrated im-
provements in quality of life in patients with CGD who had
successfully undergone curative treatment with hematopietic
stem cell transplantation, compared with those who continued
with conservative prophylactic antimicrobial and anti-
inflammatory treatment [2]. Furthermore, we, and others, have
demonstrated that many carriers of X-linked CGD experience
significant inflammatory, autoimmune, and more rarely infec-
tious symptoms as a result of lyonization, leading to dual
neutrophil populations exhibiting normal and diminished or
absent function associated with inflammation [4, 5]. Our study
is the first to investigate health-related quality of life and emo-
tional health in any cohort of carriers of a primary immuno-
deficiency. Given that we now appreciate that X-linked CGD
carriers have their own mutated gene–related disease issues, it
is perhaps not surprising that many of them exhibit a reduced
health-related quality of life, similar to that of adult CGD
patients, and worse than UK normal controls.
There are many factors that may impact upon the psycho-
logical health of XL-CGD carriers, including being a caregiver
for a child with chronic illness, genetic guilt, the presence of
anxiety and depressive symptoms, and potential ill health of the
subject themselves. Whilst there is no literature specifically
about XL-CGD carriers in this area, there is literature from
other conditions, which may be relevant to XL-CGD carriers.
Caring for a child with a chronic illness increases levels of
stress. It is less clear what that impact may be on other markers
of psychological health including the presence of anxiety and
depression. Having a child with a chronic condition impacts
upon the psychological health of the family [19]. Parental stress
has been evaluated following HSCT of a child for malignant
disease and primary immunodeficiency [20]. Mothers were
more prone to general stresses even 5 years after their child’s
HSCT but do not report higher stress scores when compared
with reference groups. Genetic guilt may account for some of
the psychological distress seen in the carers of genetic disor-
ders, but if this were the main cause, one would expect to see
lower levels of distress in conditions where there is no such
definitive inheritance. This does not appear to be true, as a study
of pediatric inflammatory bowel disease patients and their par-
ents found high levels of caregiver stress, with highest levels
seen where the disease was most active [21]. We have previ-
ously demonstrated that fatigue in carriers does not correlate
with the disease status of the index case, as those with sons
who had been successfully transplanted also exhibited symp-
toms [6], suggesting that intrinsic factors also play a part. In this
study, symptoms were found in siblings, which were no differ-
ent to those in mothers or grandmothers, again suggesting that
intrinsic factors play a role, rather than Bgenetic guilt.^ Our
findings of significantly reduced QoL in XL-CGD carriers
compared with UK population norms, and comparable with
that of adult CGD patients, are important, as it highlights an
unrecognized and unmet need that needs to be addressed in
these women. Whilst there are many factors that may have
contributed to these findings, an increased awareness of these
findings should aid clinicians in caring for the entire family,
including female relative carriers, and to institute appropriate
Table 5 Comparison and anxiety
and depression scores in XL-
CGD carriers with published data
of carers of cystic fibrosis
XL-CGD
carriers
SLE
(high pain) [12]
SLE
(low pain) [12]
SLE [13] CF carers [14]
Number 60 20 64 120 650
Age (years) 42.5 45.9 45.9 38 40.35
Depression score (mean) 5.08 8 3 6 4.36
p value 1.0 < 0.01 0.98 0.084
Mean anxiety score 9.54 9 4 9 7.52
p value 0.18 < 0.01 0.18 0.0002
Table 4 Anxiety and depression categories in XL-CGD carriers
HAD anxiety
category (score)
Number of
carriers (%)
HAD depression
category (score)
Number of
carriers (%)
Normal (0–7) 21 (34.4) Normal (0–7) 45 (73.8)
Mild (8–10) 14 (23) Mild (8–10) 11 (18)
Moderate (11–14) 22 (36.1) Moderate (11–14) 4 (6.6)
Severe (> 14) 4 (6.5) Severe (> 14) 1 (1.6)
Total 61 (100) Total 61 (100)
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measures as indicated [22]. It would be interesting to studyQoL
in other X-linked primary immunodeficiencies. In that respect,
chronic granulomatous disease may be unique—to date, it
seems to be the only disease where XL carriers may exhibit
symptoms regardless of degree of lyonization. Furthermore,
CGD is one of few diseases where there may be a reasonable
mix between transplanted and non-transplanted patients—in
Wiskott-Aldrich syndrome, common gamma chain–deficient
severe combined immunodeficiency, and X-linked lymphopro-
liferative disease, the majority of patients are transplanted or
deceased. Perhaps CD40L-deficiency is most similar in this
regard, although carriers appear asymptomatic—it is however
less common than XL-CGD, and gathering meaningful cohorts
of patients and carriers will be more challenging.
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